Ontology highlight
ABSTRACT: Importance
Treatment with immune checkpoint inhibitors (ICIs) has increased survival in patients with advanced malignant melanoma but can be associated with a wide range of immune-related adverse events (irAEs). The role of human leukocyte antigen (HLA)-DR alleles in conferring irAE risk has not been well studied.Objective
To evaluate the association between irAEs and treatment response, survival, and the presence of HLA-DR alleles after ICI therapy in advanced melanoma.Design, setting, and participants
This case-control study used the patient registry and biobanked samples from the tertiary referral University of Colorado Cancer Center. Specimens and clinical data were collected between January 1, 2010, and December 31, 2021. Patients with advanced (stage III unres
SUBMITTER: Akturk HK
PROVIDER: S-EPMC9856415 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature